Novo– tag –
-
Obesity Drug Updates Part 2: Pricing and Reimbursement of GLP-1 Obesity Drugs Across Japan, the U.S., and Europe
Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ... -
Biotech Investment News: Novo Nordisk’s Major Deals from 2015 to 2025
Strategic Overview: Expanding from Diabetes to Obesity, RNA, and Cardiometabolic Disease Novo Nordisk, known for its leadership in GLP-1 receptor agonists (Ozempic, Wegovy), has expanded significantly over the past decade. Through acquis...
1